Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 24;16(5):e1002814.
doi: 10.1371/journal.pmed.1002814. eCollection 2019 May.

Predicting progression to active tuberculosis: A rate-limiting step on the path to elimination

Ajit Lalvani  1   2 , Luis C Berrocal-Almanza  1 , Alice Halliday  2   3
Affiliations

Predicting progression to active tuberculosis: A rate-limiting step on the path to elimination

Ajit Lalvani et al. PLoS Med. .

Abstract

In a Perspective, Ajit Lalvani and colleagues discuss new approaches to predicting progression to active tuberculosis.

PubMed Disclaimer

Conflict of interest statement

I have read the journal's policy and the authors of this manuscript have the following competing interests: AL is named inventor on patents pertaining to T-cell-based diagnosis, including current and second-generation IGRA technologies and flow-cytometric diagnosis and prognosis of tuberculosis infection and disease. Some of these patents were assigned by the University of Oxford, Oxford, UK, to Oxford Immunotec plc, resulting in the T-SPOT.TB test with royalty entitlements for the University of Oxford and AL. AH is named inventor on a patent pertaining to flow-cytometric diagnosis and prognosis of tuberculosis infection and disease. LBC has declared no competing interests exist.

References

    1. World Health Organization (WHO). Global tuberculosis report 2018. 2018 [cited 2019 Mar 22]. Available from: http://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng....
    1. Abubakar I, Drobniewski F, Southern J, Sitch AJ, Jackson C, Lipman M, et al. Prognostic value of interferon-gamma release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infect Dis. 2018;18(10):1077–87. 10.1016/S1473-3099(18)30355-4 - DOI - PMC - PubMed
    1. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. New Engl J Med. 2011;365(23):2155–66. 10.1056/NEJMoa1104875 - DOI - PubMed
    1. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019;380(11):1001–11. 10.1056/NEJMoa1806808 - DOI - PMC - PubMed
    1. World Health Organization (WHO). Consensus meeting report: development of a target product profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. Report no. WHO/HTM/TB/2017.18 2018 [cited 2019 Mar 22]. Available from: http://www.who.int/iris/handle/10665/259176.

MeSH terms

Substances